US Earnings Financial Results SEC Filings — March 16, 2026

16-03-2026

Alto Neuroscience reported a net loss of $63.2M for the year ended December 31, 2025, widening 3% YoY from $61.4M, primarily due to lower interest income, interest expense, and a $0.7M loss on debt extinguishment, despite a 3% reduction in total operating expenses to $66.4M from $68.6M. Cash and equivalents increased 5% to $176.5M, bolstered by $60.1M in financing activities including a private placement, though net cash used in operations rose 9% to $51.8M. Stockholders' equity remained nearly flat at $151.1M, down slightly from $151.5M.

• ·Term loan increased to $16.7M non-current from $10.3M.
• ·Stock-based compensation expense rose to $8.1M from $7.6M.
• ·Private placement proceeds $50.0M net of costs.
• ·IPO in 2024 raised $133.0M net.
• ·Total liabilities increased to $33.5M from $26.1M.

16-03-2026

Townsquare Media reported net revenue of $427.4M for 2025, down 5.2% YoY from $451.0M, primarily due to a 12.6% decline in Broadcast Advertising revenue while Digital Advertising grew 1.6% and Subscription Digital Marketing Solutions was flat at -0.7%. Operating income more than doubled to $44.2M (up 103.8% YoY) from cost reductions including lower impairments (-76.4%) and stock-based compensation (-19.8%), narrowing net loss to $9.8M (-10.8% YoY). However, cash from operations fell 37.2% to $30.6M, cash equivalents dropped to $4.8M, and interest expense rose 32.3% to $47.9M.

• ·Total stockholders’ deficit widened to $41.0M from $28.4M.
• ·Impairment charges decreased 76.4% to $8.9M.
• ·Transaction and business realignment costs increased 137.5% to $11.7M.
• ·Basic and diluted loss per share improved to $(0.71) from $(0.81).

16-03-2026

Consolidated revenue decreased 34% YoY to $6.2M for the year ended December 31, 2025, from $9.4M in 2024, due to strategic discontinuation of unprofitable pathology services and cost reductions. However, CyPath® Lung testing revenue grew 87% YoY to $963K from $516K, driven by a 99% increase to more than 1,200 test results delivered. The company raised $16.9M in gross proceeds from equity transactions to fund operations.

16-03-2026

PCB Bancorp reported net income of $37.5M for the year ended December 31, 2025, up 45% YoY from $25.8M in 2024, with net interest income increasing 17% to $104M and total assets growing 7% to $3.28B alongside loans held-for-investment up 7% to $2.82B. Return on average assets improved to 1.15% and efficiency ratio declined to 51.2% from 60.2%. However, nonaccrual loans rose 69% to $7.9M, NPAs increased to 0.24% of assets from 0.15%, provision for credit losses grew 18% to $4.0M, and capital ratios were slightly lower though still well above regulatory thresholds.

• ·Earnings per common share diluted $2.58 for 2025, up from $1.74 in 2024.
• ·Cash dividends declared per common share $0.80 for 2025, up from $0.72.
• ·Dividend payout ratio 30.89% for 2025, improved from 41.14%.
• ·All capital ratios remain well capitalized per PCA thresholds.
• ·ASC 326 adoption increased total ACL on loans by $1.1M to $26.0M.

16-03-2026

Aemetis, Inc. (AMTX) reported mixed FY 2025 results compared to FY 2024, with California Ethanol volumes declining 6.6% to 57 million gallons and 9.0% for WDG to 374 thousand tons, while average prices rose slightly for ethanol (+3.6% to $2.03/gallon) but fell for WDG (-9.2% to $80.1/ton). India Biodiesel saw sharp drops in volumes (-71.6% to 21 thousand metric tons, capacity utilization -72% to 14%) and refined glycerin (-84.6% to 1.0 thousand tons), though glycerin prices surged 69.5% to $1,093/ton. Positively, California Dairy RNG gas sales grew 32.1% to 399 thousand MMBtu (+11.0% price) and LCFS credits rose 59.6% to 83 thousand, offsetting declines despite RIN prices falling 17.8%.

• ·California Ethanol operated at 104% of nameplate capacity in FY 2025 vs 110% in FY 2024 (-5.9%).
• ·India Biodiesel operated at 14% of nameplate capacity in FY 2025 vs 50% in FY 2024 (-72%).

16-03-2026

Figure Technology Solutions, Inc. (FIGR) reported robust FY2025 financials with net revenue surging 48.7% YoY to $507M from $341M and net income skyrocketing 574.3% to $134M from $20M, fueled by ecosystem volume growth to $9.1B from $5.9B and strong gains in ecosystem/technology fees (+327%) and partner-branded revenue (+86.8%). However, digital asset marketplace volume declined to $710M from $751M, gain on servicing assets fell 24.7% to $25M, and partner-branded origination fees dropped 10.2%, while several expense categories like operations (+46.4%) and sales/marketing (+36.7%) rose notably. Adjusted EBITDA improved sharply to $251M from $101M, reflecting operational leverage despite mixed segment performance.

• ·Operating income increased 1172.6% to $118M from $9M.
• ·Interest expense declined 13.4% to $49M.
• ·Sales and marketing expenses rose 36.7% to $76M, driven by 80.2% higher compensation.
• ·Technology and product development expenses up modestly 3.6% to $65M.

16-03-2026

LivePerson Inc (LPSN) reported FY 2025 revenue of $243.7M, down 22% YoY from $312.5M amid broad declines. Operating expenses decreased significantly across categories, including cost of revenue -10%, sales and marketing -22%, general and administrative -44%, product development -31%, depreciation and amortization -46%, and goodwill impairment -31%, driven by headcount reductions (e.g., product development headcount down 41% to 239). Restructuring costs edged up 5% YoY to $11.7M.

16-03-2026

The 21Shares Dogecoin ETF (TDOG) filed its annual 10-K for the period from inception on September 17, 2025, to September 30, 2025, reporting total assets, net assets, and paid-in capital of $100, with 2 shares issued and outstanding at a net asset value per share of $50.00. No net investment loss, unrealized gains/depreciation, or redemptions occurred during this short inaugural period. However, the filing highlights risks from pseudonymous Dogecoin ownership and potential large-scale sales by substantial holders, which could adversely impact Dogecoin price and ETF shares.

• ·Filing CIK: 0002064314
• ·Entity File Number: 001-43049
• ·Entity Tax ID: 33-7038007
• ·Incorporated in MD
• ·Address: 477 Madison Avenue, 6th Floor, New York, NY 10022
• ·Phone: (646) 370-6016

16-03-2026

WaterBridge Infrastructure LLC reported total revenues of $525.6M for the year ended December 31, 2025, up 66% YoY from $316.3M, driven by produced water handling revenues surging 66% to $471.6M and total volumes increasing 64% to 1,920 MBbl/d. However, net income plummeted nearly 100% to $9K from $3.0M due to a 29% rise in net interest expense to $68.9M, a $11.4M loss on debt extinguishment, and higher depreciation (80% up), while gross margin per Bbl declined 5% to $0.20 and skim oil unit prices fell 25%. Adjusted EBITDA grew 68% to $254.0M with a flat 48% margin.

• ·Produced water handling volumes: 1,622 MBbl/d in 2025 (62% YoY increase from 1,002 MBbl/d).
• ·Water solutions volumes: 298 MBbl/d in 2025 (76% YoY increase from 169 MBbl/d), with brackish water up 162%.
• ·Predecessor period (Jan 1 - Sep 16, 2025) revenues: $242.6M, down 26% from full year 2024 $329.4M.
• ·Depreciation, depletion, amortization, and accretion: $140.9M in 2025 (80% YoY increase).

16-03-2026

CO2 Energy Transition Corp., a SPAC, reported net income of $1.65M for FY 2025, up significantly from $2.6K in 2024, driven by $2.88M in interest income on Trust Account investments which grew to $72.1M from $69.3M. However, cash declined 70% to $288K, G&A expenses rose 163% to $646K leading to higher operating losses, and stockholders' deficit worsened 42% to $(1.79M). Total assets increased modestly to $72.5M, primarily from accretion on 6.9M redeemable shares now at $10.35/share.

• ·Net cash used in operating activities increased to $745K in 2025 from $306K in 2024.
• ·Income tax provision rose to $579K in 2025 from $61K in 2024.
• ·Deferred underwriting fee steady at $2.07M.

16-03-2026

Blend Labs reported total revenue of $123.6M for FY 2025, up 7% YoY from $115.8M, driven by 34% growth in Consumer Banking Suite to $45.2M, though Mortgage Suite declined 6% to $69.2M and Professional Services grew modestly 3%. Gross profit rose 10% to $91.2M with margin expansion to 74%, operating expenses fell 15% to $112.9M, and net loss narrowed sharply to $7.0M from $43.4M YoY. Operating cash flow turned positive at $14.4M versus negative $8.2M prior year.

• ·Software platform revenue $114.4M (93% of total) in FY 2025, up from $106.9M in 2024.
• ·R&D expenses down 29% YoY to $32.8M; Sales & marketing down 16% to $29.1M; G&A up 10% to $50.1M.
• ·No interest expense in FY 2025 vs $6.7M in 2024.
• ·Net cash decrease of $2.5M in FY 2025 after $11.3M increase in 2024.
• ·Stock-based compensation $29.0M in FY 2025, down from $27.9M in 2024 but up from $45.6M in 2023.

16-03-2026

Mountain Crest Acquisition Corp. V reported a widened net loss of $431,161 for the year ended December 31, 2025, up 15% YoY from $374,454 in 2024, driven by sharply lower interest income on the Trust Account ($46,114 vs. $265,306). While general and administrative expenses declined 24% to $471,782 and net cash used in operating activities improved to $742K from $921K, total assets fell to $874K from $1.3M, cash dropped to $12K, and the Trust Account balance decreased 27% to $841K amid ongoing redemptions reducing redeemable shares to 72,123 from 101,104. Stockholders' deficit worsened to $(3.7M) from $(3.4M), with related-party promissory note rising to $1.3M.

• ·Proposal to amend Charter to extend Combination Period to November 16, 2024 with $0.10 per Public Share deposits for three-month extensions.
• ·Deferred underwriting commission obligation of $2.07M upon business combination.
• ·Conversion of $600K related-party promissory note to equity in 2024.
• ·Reversal of $194K excise tax payable in 2025.
• ·Net cash provided by investing activities $363K in 2025 (vs $4.72M in 2024), mainly from $336K redemption withdrawals.

16-03-2026

Vanguard Green Investment Ltd reported zero revenue for both the three and six months ended January 31, 2026, with net losses widening significantly to $30,132 (3M, +125% YoY) and $47,129 (6M, +62% YoY) due to elevated general and administrative expenses. Total assets contracted 66.5% to $5,110 from $15,258 as of July 31, 2025, while cash equivalents dropped to $55 from $93; stockholders' deficit deepened to $(771,707) from $(724,578). Non-current liabilities improved with a 48% reduction to $18,093, but current liabilities rose 7.6% to $758,724, largely from increased director loans.

• ·Prepayments decreased to $5,055 from $15,165 as of Jul 31, 2025.
• ·Loan from director increased to $484,543 from $445,001.
• ·Amount due to related parties remained flat at $96,513.
• ·G&A expenses for six months rose to $43,495 from $23,698 YoY.

16-03-2026

Dollar Tree, Inc. reported FY2026 (year ended January 31, 2026) net sales of $19.4B, up 10.4% YoY from $17.6B, with comparable store sales growth of 5.3% driven by 1.0% traffic increase and 4.3% higher average ticket. Operating income rose 13.1% to $1.65B with a 8.5% margin (up 20bps YoY but down from 10.6% in FY2024), while gross margin expanded 60bps to 36.4%; however, SG&A expense rate climbed to 28.2% from 27.5% YoY, and customer traffic growth slowed to just 1.0%. Income from continuing operations increased to $1.2B, up ~17.5% YoY.

• ·Net sales per selling square foot increased to $241 in FY2026 from $232 in FY2025 but remained below FY2024's $234.
• ·Other revenue was $16.1M in FY2026, up from $12.7M in FY2025.
• ·Transition services agreement income, net: $54.9M in FY2026.

16-03-2026

Forgent Intermediate LLC reported strong revenue growth of 69% YoY to $296,404 for the three months ended December 31, 2025, with gross profit up 60% to $101,756, but operating income grew only 6% to $20,090 amid higher SG&A expenses, resulting in a net loss of $91 versus prior year profit of $6,431 due to elevated interest expense. For the six months ended December 31, 2025, revenues surged 76% YoY to $579,678, yet net income attributable to the LLC dipped 6% to $10,259, cash from operations plummeted 90% to $6,007, and cash balance declined to $106,165 from $111,322 at June 30 and $215,837 prior year.

• ·Long-term debt increased to $579,006 (net) at Dec 31, 2025 from $496,934 at Jun 30, 2025, with $594,000 proceeds offset by $511,110 payments.
• ·Capex rose to $56,368 for 6M ended Dec 31, 2025 from $24,376 prior year.
• ·Accounts receivable increased to $251,017 at Dec 31, 2025 from $159,970 at Jun 30, 2025.

16-03-2026

KEEMO Fashion Group Ltd reported no revenue for the six months ended January 31, 2026, down 100% from $9,957 in the prior year, leading to a net loss of $30,239 (62% worse than $18,655) and comprehensive loss of $51,602 amid sharply higher G&A expenses ($30,238 vs $23,621). The company completed an acquisition of GW Reader Sdn. Bhd., adding $293,498 in goodwill and $29,687 in cash acquired, boosting total assets to $322,644 and cash to $22,696, but operating cash flow deteriorated to $(47,982) from $2,454 while liabilities surged to $610,298 (driven by $560,908 due to related parties) and shareholders' deficit widened to $(287,654). Three-month net loss also worsened to $(17,803) from $(10,254) with zero revenue versus $5,012 previously.

• ·No income taxes or interest paid in the period.
• ·Weighted average shares outstanding: 55,000,000 (basic and diluted).
• ·Fair value of GW Reader Sdn. Bhd. net liabilities: $(293,500), resulting in goodwill of $(293,498).

16-03-2026

Crona Corp. (CCCP) reported no revenue for the three and nine months ended September 30, 2025, with operating expenses increasing significantly to $25,775 (up 148% from $10,414) and $128,800 (up 193% from $43,962) year-over-year, driven by higher professional fees ($81,125 vs. $14,613). However, a one-time debt forgiveness of $151,710 resulted in net profits of $82,027 (3M, vs. $16,151 loss) and $9,321 (9M, vs. $61,096 loss). Total assets declined 56% to $17,179 from $39,076 at December 31, 2024, amid substantial going concern doubts and reliance on related party advances.

• ·Cheung Lam Hung beneficially owns ~75.90% of common shares via Next Talent (HK) Limited following March 7, 2025 acquisition of 5M shares.
• ·Convertible promissory note issued Feb 9, 2023: face $132,000 at 12% interest, maturity Feb 9, 2024.
• ·Related party promissory note of $100,000 repaid in 2025.
• ·No cash on hand; net cash used in operations $116,381 offset by related party advances.
• ·7,087,600 common shares outstanding as of Nov 11, 2025.

16-03-2026

CytomX Therapeutics' total revenue declined 45% YoY to $76.2M in 2025 from $138.1M in 2024, driven by sharp drops in collaborations with Bristol Myers Squibb (-46%), Astellas (-39%), Regeneron (-40%), and Moderna (-99.8%), though Amgen revenue surged 222% to $9.8M. The company swung to a net loss of $17.4M from a $31.9M profit, with operating expenses down 13% to $98.6M due to lower R&D (-18%), while G&A remained flat. However, strong financing activities raised $110.4M, boosting total assets 26% to $151.6M and flipping stockholders' equity to a positive $99.0M from a near-zero deficit.

• ·Net cash used in operating activities improved to $75.6M from $86.2M YoY.
• ·Net cash from investing activities was a use of $59.7M vs provision of $99.7M in 2024.
• ·Deferred revenue dropped sharply to $28.5M current + $1.6M long-term from $94.1M total.
• ·Basic EPS was -$0.15 vs $0.38 YoY; weighted average shares 138M vs 84M.
• ·Auditors highlighted judgment in revenue recognition for collaboration agreements using input method.

16-03-2026

Contango ORE, Inc. reported a net loss of $36.1M for FY2025 ended December 31, 2025, improved from $38.0M in 2024, supported by Peak Gold JV equity income of $88.6M (up 112% YoY) and cash distributions of $102M (up 152% from $40.5M), alongside gold sales of $196.7M from 57,800 oz (30% share) at an average realized price of $3,400/oz. However, losses on derivative contracts surged to $109.1M from $54.2M, cash costs per ounce rose 21% YoY to $1,459, and AISC per ounce increased 34% YoY to $1,616 amid higher total costs. Total assets grew 28% to $172M with cash equivalents up 223% to $64.8M, though derivative liabilities ballooned to $103.7M and investment in Peak Gold declined to $47.1M from $60.5M.

• ·Gold ounces sold at spot price: 14,061 oz; into hedge contracts: 43,739 oz; remaining hedged balance: 43,000 oz.
• ·Total current liabilities $76.3M (2025) vs $75.8M (2024); derivative contract liability $103.7M total (up significantly).
• ·Weighted average common shares outstanding: 12,902,668 (2025) vs 10,896,228 (2024).
• ·Net cash provided by operating activities: $25.7M (2025) vs $0.7M (2024).

16-03-2026

Olema Pharmaceuticals reported a widened net loss of $162.5M for the year ended December 31, 2025, up 25% from $129.5M in 2024, primarily due to a 27% increase in R&D expenses to $157.7M (including a $10M milestone payment to Aurigene) and 18% higher G&A expenses. Operating cash use rose 41% to $146.7M amid heavier investing outflows, resulting in a $91.2M net decrease in cash and equivalents to $48.3M; however, marketable securities expanded 55% to $457.1M, total assets grew 18% to $533.4M, and financing activities provided $211.3M, lifting stockholders' equity 17% to $478.6M.

• ·Net loss per share improved to $(1.87) from $(2.20) due to 48% increase in weighted average shares.
• ·Follow-on public offering raised $204.8M net (11.5M shares).
• ·Report of Independent Registered Public Accounting Firm by Ernst & Young LLP (PCAOB ID No. 42).

16-03-2026

WW International, Inc. reported net revenue of $347.1M for the Successor period (June 25 to December 31, 2025), down 4.6% from $363.6M in the comparable Predecessor period (December 29, 2024 to June 24, 2025), while combined FY2025 subscription revenue fell 9.2% YoY to $705.4M amid a 15.2% decline in Behavioral revenue and 18.9% drop in end-of-period Behavioral subscribers, offset by 44.7% growth in Clinical revenue and subscribers. The company recorded a net loss of $62.1M in the Successor period versus a $1,118.1M gain in Predecessor due to reorganization items, with operating margin turning negative at -0.7% from 5.8%, though cash position strengthened to $160.3M from $53.0M and working capital improved to a $87.1M surplus.

• ·Gross margin declined to 71.2% in Successor period from 72.4% in Predecessor.
• ·Franchise rights impairments: $0M Successor vs $27.5M Predecessor and $315.0M FY2024.
• ·Reorganization items net: $0M Successor vs ($1,143.9M) Predecessor.
• ·Net cash from operating activities: $5.5M Successor vs ($34.4M) Predecessor.
• ·Working capital surplus $87.1M at Dec 31, 2025 vs deficit ($70.7M) at Dec 28, 2024.
• ·Diluted EPS: ($6.22) Successor vs $13.80 Predecessor.

16-03-2026

Zenas BioPharma reported license and collaboration revenue of $10K for the year ended December 31, 2025, doubling from $5K in 2024. However, net loss widened dramatically to $378M from $157M, driven by a one-time $172M acquired in-process R&D expense, R&D expenses up 21% to $168M, and G&A up 79% to $53M, resulting in operating loss of $383M versus $164M prior year. Cash and equivalents fell 65% to $111M from $320M, with net cash used in operations increasing 44% to $172M and investing activities using $252M.

• ·Weighted-average common shares outstanding increased to 44.7M in 2025 from 13.2M in 2024.
• ·Equity consideration for InnoCare License Agreement valued at $137M.
• ·Total assets grew slightly to $384M from $370M; stockholders' equity declined to $242M from $312M.
• ·Product candidate license acquisitions of $35M in investing activities.

16-03-2026

OPAL Fuels Inc. reported total revenues of $349M for FY 2025, up 16% YoY from $300M, driven by strong growth in RNG Fuel (+15% to $102M) and Fuel Station Services (+29% to $215M), while Renewable Power revenues declined 27% to $33M. Operating income fell 65% to $7.4M due to higher operating expenses (+23%), though net income rose 154% to $36.4M boosted by a $53M income tax benefit; net income attributable to Class A common stockholders increased to $4.3M (+663%). Total assets grew 9% to $959M, with net cash from operating activities up 16% to $36.5M.

• ·Net cash used in investing activities improved to $(77M) from $(135M) YoY.
• ·Redeemable non-controlling interests decreased to $378M from $483M.
• ·Loans, net of debt issuance costs, increased to $337M from $285M.
• ·Income tax benefit surged 492% to $53M.
• ·Property, plant, and equipment, net, grew to $496M from $458M.
• ·Impairment loss was $0 in 2025 vs. $2M in 2024.

16-03-2026

Orange County Bancorp, Inc. reported net income of $41.6 million for the year ended December 31, 2025, a 49.2% YoY increase from $27.9 million, fueled by net interest income growth of 13.4% to $104.1 million and noninterest income surge of 44.9% to $23.1 million. Average total assets expanded to $2.59 billion from $2.48 billion, with net interest margin improving to 4.18% from 3.83%. However, non-performing loans rose sharply to $11.1 million from $6.3 million, lifting the NPL to total loans ratio to 0.57% from 0.35%, and noninterest expenses increased 4.1% to $67.9 million.

• ·Banking segment net income $37.5M in 2025 vs $25.4M in 2024; Wealth Management $4.1M vs $2.5M.
• ·Provision for credit losses $7.7M in 2025, down 19.4% from $9.6M.
• ·Non-accrual commercial real estate loans $8.7M at Dec 31 2025 vs $6.0M at Dec 31 2024.
• ·Investment securities gains (losses) -$0.6M in 2025.
• ·Proceeds from bank owned life insurance $3.6M in 2025 (new).
• ·Total assets at Dec 31 2025 $2.66B vs $2.51B at Dec 31 2024.

16-03-2026

Embassy Bancorp, Inc. reported total assets of $1.80B as of Dec 31, 2025, up 5.6% YoY from $1.70B, driven by loan growth to $1.28B net (up 1.8%) and deposits to $1.64B (up 5.6%), with net interest income rising 17.2% YoY to $42.4M and net interest margin expanding to 2.52% from 2.26%. Stockholders' equity increased 19.9% to $127.6M, supported by retained earnings growth and reduced accumulated other comprehensive loss. However, nonperforming loans remained flat at 0.04% of total loans, and certain yields like interest-bearing deposits declined to 4.28% from 5.32%.

• ·Average taxable loans: $1.25B in 2025 (up from $1.24B), interest $57.3M (up 7.3%).
• ·Securities available for sale: $342M at Dec 31, 2025 (up from $281M).
• ·Allowance for credit losses: $12.0M at Dec 31, 2025 (down slightly from $12.2M).
• ·Net charge-offs to average loans: 0.01% in 2025 (vs -0.02% recovery in 2024).

16-03-2026

HeartSciences Inc. reported a narrowed net loss of $6.4M for the nine months ended January 31, 2026, compared to $6.7M prior year (-4% improvement), driven by reduced R&D expenses (-32% YoY to $2.4M) while SG&A rose 18% to $3.5M; cash and equivalents surged 209% to $3.4M, bolstered by $8.1M in financing inflows including $5.5M from Series D preferred stock. However, revenue remained negligible at $4K for the nine months (vs $0), with no revenue in Q3, and total liabilities increased to $4.9M amid higher notes payable. Stockholders' equity improved significantly to $2.7M from $0.2M, supported by equity issuances and conversions.

• ·Common shares outstanding increased to 3,184,207 from 1,119,107 at Apr 30, 2025.
• ·Warrants outstanding rose to 2,102,659 with weighted average exercise price $9.64.
• ·Inventory remained flat at ~$657K; property and equipment net declined to $46K from $64K.

16-03-2026

Black Diamond Therapeutics achieved net income of $22.4M in 2025, reversing a $69.7M loss in 2024, fueled by $70M in new license revenue and sharp cuts in operating expenses (R&D down 35% to $33.6M, G&A down 40% to $16.6M). However, cash and equivalents fell 42% to $21.0M amid a $44.9M outflow in investing activities, and the company recorded a $7.3M impairment charge. Total assets expanded 17% to $143.0M, supported by investments surging 73% to $107.7M, while stockholders' equity rose 35% to $112.2M.

• ·Net income per share basic/diluted: $0.39 (2025) vs $(1.27) (2024)
• ·Weighted average shares basic: 56.9M (2025) vs 55.0M (2024)
• ·Stock-based compensation: $6.6M (2025) down from $10.6M (2024)

16-03-2026

Telos Corp (TLS) reported FY2025 revenue of $164.8M, up 52% YoY from $108.3M, primarily driven by Security Solutions segment growth of 95% to $149.6M, while Secure Networks segment revenues declined 52% to $15.2M. Gross margin improved to 37.0% from 31.8%, Adjusted EBITDA turned positive at $18.1M versus -$9.6M prior year, and operating cash flow swung to $30.2M from -$25.9M; however, the company recorded a net loss of $36.5M (improved from $52.5M), including a $14.9M goodwill impairment.

• ·Products revenue grew to $28.3M from $4.7M YoY.
• ·Services revenue increased to $136.5M from $103.6M YoY.
• ·Basic and diluted EPS improved to -$0.50 from -$0.73.
• ·Net cash used in investing activities $8.9M (improved from $16.8M).

16-03-2026

NATURAL GAS SERVICES GROUP INC (NGS) reported FY2025 total revenues of $172.3M, up 10% YoY from $156.7M, primarily driven by rental revenues surging 13.9% to $164.3M with rented horsepower up 14.4% to 562,676 and utilization improving to 84.9%. Adjusted EBITDA increased 16% to $81.0M and net income rose to $19.9M from $17.2M. However, sales revenues plummeted 47.6% to $4.0M with negative adjusted gross margin of -$0.2M, and aftermarket services declined 18.3% to $4.0M despite margin improvement.

• ·Fleet horsepower available at period end increased to 662,542 in 2025 from 598,840 in 2024 (+10.6%).
• ·Unit utilization at period end rose slightly to 65.0% from 63.2% (+1.8%).
• ·Impairments increased to $2.6M in 2025 from $0.8M in 2024.
• ·SG&A expenses as % of revenues improved slightly to 13.0% from 13.4%.
• ·Depreciation and amortization rose 16.9% to $36.7M.

16-03-2026

Eve Holding, Inc. reported a widened net loss of $224.3M for the year ended December 31, 2025, up 62% from $138.2M in 2024, driven by research and development expenses surging 50% to $194.7M and SG&A expenses rising 16% to $30.7M, resulting in an operating loss of $225.4M (44% worse YoY). While financial investment income increased 33% to $16.4M and net cash from financing activities rose to $263.1M, cash used in operations grew to $160.4M and the company remains pre-revenue with ongoing eVTOL development risks.

• ·Cash used in investing activities decreased to $46.7M in 2025 from $56.2M in 2024.
• ·Related party loan interest income declined to $0 in 2025 from $2.9M in 2024 (100% decrease).
• ·Interest expense increased to $10.1M in 2025 from $3.7M in 2024 (177% unfavorable).
• ·BRL-denominated loans and financing carrying value $38.7M at Dec 31, 2025 (potential gain $2.6M at exchange rate 5.5024).

16-03-2026

Cue Biopharma's collaboration revenue surged 196% YoY to $27.5M in 2025 from $9.3M in 2024, driving a narrower net loss of $26.6M (improved 35% YoY) and loss from operations of $26.6M versus $41.5M prior year. However, total operating expenses rose 6% to $54.0M, with G&A up 11% to $16.2M and R&D up 4% to $37.7M, while cash burn from operations improved but remained high at $21.7M used. Cash and equivalents increased to $27.1M from $22.5M, supported by $26.3M in financing, though common shares outstanding nearly doubled to 96.6M, causing dilution.

• ·Net loss per common share improved to $(0.28) from $(0.72) YoY.
• ·Total stockholders’ equity increased to $26.4M from $17.5M.
• ·Current liabilities slightly decreased to $13.5M from $13.7M.
• ·Repaid $4.5M in term loans in 2025.
• ·Stock-based compensation expense declined to $4.7M from $6.8M.

16-03-2026

Kaltura Inc (KLTR) reported total revenue of $180.9M for FY 2025, up 1% YoY from $178.7M, driven by 4% growth in Enterprise, Education & Technology to $134.4M, but offset by a 7% decline in Media & Telecom to $46.4M. Gross profit rose 7% to $127.7M amid cost reductions, narrowing net loss to $12.1M (61% improvement YoY), with Adjusted EBITDA turning strongly positive at $18.6M versus $7.3M prior year. However, Remaining Performance Obligations fell to $166.3M from $176.9M, and ARR dipped to $168.2M from $173.9M.

• ·Net cash provided by operating activities: $14.5M in FY2025 (up from $12.2M in FY2024).
• ·Net cash from investing activities: $9.1M in FY2025 (vs $(12.4)M in FY2024).
• ·Restructuring expenses: $0.9M in FY2025.
• ·Strategic initiatives expenses: $1.3M in FY2025.
• ·Acquisition related expenses: $0.4M in FY2025.

16-03-2026

The 10-K annual report includes Appendix B, a detailed assessment of compliance with Regulation AB servicing criteria (1122(d)) for asset-backed securities across multiple entities including the Company, Platform (sections A, B, C), PBLS, CoreLogic, and Midland. Most general servicing considerations, cash collection, pool asset administration criteria are marked as performed directly (X) or by responsible vendors, while several investor remittances and reporting criteria (e.g., 1122(d)(3)(i)(B)-(D), (ii)-(iv)) are noted as not performed by the Company or subservicers. No material deficiencies, exceptions, or financial impacts are disclosed in the tables.

16-03-2026

For the three months ended January 31, 2026, Coffee Holding Co Inc reported net sales of $25.6M, up 20% YoY from $21.3M, driven by strong Packed coffee segment growth of 35% to $16.7M, while Green coffee sales were essentially flat down 0.7% to $8.8M. Net income rose 43% YoY to $1.6M with EPS at $0.29, and operating cash flow surged to $6.6M from a $0.4M use; however, the company paid a $0.08 per share dividend totaling $0.47M and inventories declined QoQ to $19.0M from $20.4M.

• ·Income from operations increased 49.5% YoY to $2.38M.
• ·Interest expense rose to $65,740 from $31,670 YoY.
• ·Net cash used in investing activities $1.16M, including $0.85M purchase of investment and $0.28M leasehold improvements.
• ·Principal payments on bank line of credit $3.4M in financing activities.
• ·Right-of-use operating lease assets $1.92M as of Jan 31, 2026.

16-03-2026

Universal Logistics Holdings, Inc. (ULH) reported 2025 operating revenues of $1.56B, down 15.6% YoY from $1.85B in 2024, swinging to a net loss of $99.9M (-6.4% margin) from $129.9M profit (7.0% margin), driven by a $124M impairment expense and a $162M operating loss in Intermodal (vs -$28M prior). While Value-Added services rose to 45.7% of revenues (from 42.6%) and Dedicated services to 21.7% (from 18.6%), Brokerage services plunged to 4.7% (from 9.8%) and Intermodal revenues fell to $257M (from $309M). In 2024, revenues had grown 11.1% YoY from $1.66B with net income up 39.8% to $129.9M.

• ·2025 EPS basic and diluted: -$3.79 (vs $4.94 in 2024)
• ·Dividends per share flat at $0.42 across 2023-2025
• ·Goodwill declined to $106M in 2025 from $207M in 2024
• ·Total stockholders' equity down to $540M from $647M
• ·Intermodal revenues down 16.7% YoY to $252M in detailed service breakdown

16-03-2026

Comtech Telecommunications Corp reported net sales of $106.8M for Q2 FY2026, down 15.6% YoY from $126.6M, and $217.8M for H1 FY2026, down 10.2% YoY from $242.4M, reflecting revenue declines. However, gross profit improved to $36.2M (+7.4% YoY) in Q2 and $73.0M (+51.3% YoY) in H1, driven by lower cost of sales, leading to a narrower operating loss of ($1.2M) in Q2 (vs. ($10.3M)) and ($4.0M) in H1 (vs. ($139.4M), aided by absence of prior-year $79.6M impairment). Net loss narrowed to ($13.6M) in Q2 and ($29.5M) in H1, with stockholders' equity at $65.6M (down from $104.4M at FY end) and cash at $32.8M (down from $40.0M).

• ·Operating cash flow improved to $12.9M in H1 FY2026 from ($22.0M) in H1 FY2025.
• ·Non-current subordinated credit facility increased to $103.5M from $95.6M at FY end.
• ·Warrant and derivative liabilities rose to $23.0M from $17.8M at FY end.
• ·Accounts receivable decreased to $127.9M from $144.8M at FY end.

16-03-2026

Once Upon a Farm, PBC reported net sales of $240.7M for the year ended December 31, 2025, up 53% YoY from $156.8M, with robust growth in Baby Snacks (+226%), Kid Snacks (+136%), and Total Baby (+95%), while Kid Pouches grew 23%. However, gross margin contracted to 42% from 44% amid 57% higher COGS, SG&A rose 44% to $107.6M (45% of sales, improved from 48%), and the net loss narrowed to $17.2M from $23.8M but cash used in operations doubled to $29.9M. Loss from operations improved slightly to $(5.7M) from $(6.3M), though other expenses including a $8.6M derivative liability hit persisted.

• ·Change in fair value of derivative liability: $(8.6M) in 2025 vs $(16.0M) in 2024
• ·Net cash provided by financing activities: $28.7M in 2025 vs $0.4M in 2024
• ·Net decrease in cash: $(6.4M) in 2025 vs $(13.6M) in 2024
• ·Baby Other sales declined 44% YoY to $2.2M

16-03-2026

Perspective Therapeutics, Inc. reported a widened net loss of $103.1M ($1.40 per share) for the year ended December 31, 2025, up 30% from $79.3M ($1.23 per share) in 2024, primarily due to R&D expenses more than doubling to $84.2M (+102% YoY) and grant revenue declining 38% to $0.9M, while total operating expenses rose 24% to $114.4M. Operating loss expanded to $113.6M from $90.9M, with cash used in operations surging to $82.5M from $18.3M, leading to cash and equivalents dropping to $30.6M from $61.6M. However, net cash from investing activities turned positive at $41.2M (vs. -$219.0M prior year) due to securities maturities, and there was no goodwill impairment in 2025 after $24.1M in 2024.

• ·In-process research and development impairment of $10.0M in 2025.
• ·Property and equipment, net increased to $76.6M from $57.3M.
• ·Weighted average shares outstanding increased 14.6% to 73.8M.
• ·Short-term investments $114.1M at Dec 31 2025 (down from $165.3M).

16-03-2026

Dell Technologies Inc. reported FY2026 total net revenue of $113.5B, up 19% YoY from $95.6B, driven by strong 27% growth in Products to $90.4B, though Services revenue declined 4% to $23.1B. Operating income increased 31% to $8.1B and net income rose 30% to $5.9B, with cash flow from operations surging 147% to $11.2B; however, product gross margin compressed to 13.7% from 15.8% YoY and total gross margin fell to 20.0% from 22.2%. Non-GAAP diluted EPS grew 27% to $10.30, while the company repurchased 14.9M shares.

• ·Share repurchases: 3.3M shares at $133.22 avg (Nov 1-28, 2025), 3.6M at $132.34 (Nov 29-Dec 26, 2025), 8.0M at $118.96 (Dec 27, 2025-Jan 30, 2026).
• ·Remaining share repurchase authorization: $5,798M as of Jan 30, 2026.
• ·Related party cost of net revenue in FY2024: $1,010M (Products), $2,810M (Services).

16-03-2026

Ardent Health, Inc. reported total revenue of $6.3B for the year ended December 31, 2025, up 6.0% YoY from $6.0B in 2024, supported by 5.3% higher admissions, 7.3% more patient days, and 8.7% increased bed utilization. However, net income attributable to the company fell 35.4% YoY to $136M from $210M, with total operating expenses rising to 95.5% of revenue from 93.9%, while Adjusted EBITDA improved 9.4% to $545M. Operating metrics showed inpatient surgeries up 6.5% but outpatient surgeries down 2.3%, resulting in flat total surgeries at +0.2%.

• ·Medicare payer mix declined to 38.6% in 2025 from 39.2% in 2024.
• ·Operating cash flow surged to $471M in 2025 from $315M in 2024.
• ·Total contractual obligations amount to $4.6B, primarily operating leases ($2.9B).

16-03-2026

Samsara Inc. reported FY2026 revenue of $1.62B, up 30% YoY from $1.25B, with gross profit rising to $1.24B and gross margin expanding to 77% from 76%. Operating expenses grew more slowly than revenue, reducing R&D, sales & marketing, and G&A as percentages of revenue, while non-GAAP operating income reached $282M (17% margin, up from 9%) and free cash flow improved to $207M (13% margin). However, provision for income taxes surged 123% to $10M, resulting in an effective tax rate of 1,106% versus (3.0%) prior year.

• ·Filing date: March 16, 2026
• ·Fiscal year end dates: January 31, 2026 (FY2026), February 1, 2025 (FY2025), February 3, 2024 (FY2024)

16-03-2026

FibroGen Inc reported total revenue of $6.4M for the year ended December 31, 2025, down 78% YoY from $29.6M in 2024, driven by an 79% drop in drug product revenue (notably AstraZeneca U.S./RoW to $0) and 70% decline in development revenue. Operating expenses fell 71% to $52.3M, with R&D down 75% and SG&A down 44%, narrowing the loss from continuing operations to $58.2M (per share $(14.40)) from $153.1M ($(38.26)). Cash and equivalents decreased slightly to $47.9M from $50.5M, with operating cash use improving to $4.8M from $138.0M but offset by $86.0M in financing outflows.

• ·Drug product revenue from AstraZeneca U.S./RoW Agreement fell to $0 from $25.7M (NM decline).
• ·Development revenue from Astellas down 58% to $0.6M; from AstraZeneca to $0 (NM).
• ·Loss on debt extinguishments of $6.6M in 2025 (none in 2024).
• ·Short-term investments $41.1M at Dec 31 2025 (none in 2024); long-term investments $20.2M (none in 2024).

16-03-2026

Zedge, Inc. reported Q2 FY2026 revenue of $8.3M, up 18.3% YoY, with Zedge Marketplace growing 21.2% to $7.7M driven by 32.5% subscription increase, while GuruShots revenue declined 11.5% to $0.5M. However, net loss widened to $2.3M from $1.7M YoY due to a $3.6M impairment of intangible assets, though H1 FY2026 showed revenue growth of 11.9% to $15.9M and reduced net loss of $1.5M vs $2.0M prior year. Total assets decreased to $33.8M from $35.7M at FY2025 end.

• ·Operating cash flow for H1 FY2026 was $1.7M, down slightly from $1.9M prior year.
• ·Treasury stock purchases totaled $0.9M in H1 FY2026.
• ·Cash dividends paid $0.2M in H1 FY2026.
• ·Intangible assets net decreased to $1.1M from $4.9M.
• ·Accumulated deficit increased to $17.0M from $15.5M.

16-03-2026

Getty Images Holdings, Inc. reported FY2025 revenue of $981.3M, up 4.5% YoY from $939.3M, driven by Editorial (+6.9% to $369.6M) and Other (+35.2% to $54.8M), while Creative remained nearly flat (+0.7% to $556.9M). However, income from operations declined 53.6% to $83.9M amid surging litigation losses (+390.4% to $100.5M) and other operating expenses (+246.3%), leading to a net loss of $206.2M versus $39.5M profit in 2024; Adjusted EBITDA improved slightly to $320.9M (32.7% margin). Cash from operations dropped 44.9% to $65.2M.

• ·LTM total purchasing customers declined to 689K in FY2025 from 717K in FY2024.
• ·LTM annual subscriber revenue retention rate fell to 89.9% in FY2025 from 92.9% in FY2024.
• ·Net cash from financing activities surged to $576.2M in FY2025 from -$56.2M in FY2024.
• ·Image collection grew to 609M in FY2025 from 572M in FY2024.

16-03-2026

Net sales declined 1.2% YoY to $19.0M for the three months ended January 31, 2026, however gross profit rose 7.1% to $6.1M driven by lower cost of sales, and operating income surged 216% to $0.2M from $0.1M. The consolidated net loss narrowed significantly to $50k from $245k YoY, with basic EPS improving to $(0.00) from $(0.02). Operating cash flow increased 44% to $0.9M, though cash and equivalents ended slightly lower QoQ at $5.1M amid higher investing and financing outflows.

• ·Customer concentration: Aerospace customer represented 11% of sales and 17% of accounts receivable in Q1 FY2026; Wireless provider B at 19% of AR.
• ·Inventories remained essentially flat QoQ at $13.8M.
• ·Capital expenditures increased to $0.2M from $0.03M YoY.
• ·Total stockholders' equity increased slightly to $35.5M as of Jan 31, 2026 from $35.2M at Oct 31, 2025.

16-03-2026

FutureFuel Corp. reported a sharp 61% YoY revenue decline to $95.7M in FY 2025 (ended Dec 31, 2025) from $243.3M in FY 2024, driven by operational challenges, resulting in a net loss of $49.4M versus net income of $15.5M and Adjusted EBITDA loss of $38.3M compared to $21.3M profit. Operating income swung to a $53.0M loss from $6.4M profit, with cash used in operations at $28.7M versus $24.8M provided. Despite the downturn, the company declared an initial quarterly dividend of $0.06 per share for Q1 2026 and emphasized chemicals segment expansion through vertical integration.

• ·Depreciation expense increased slightly 5% YoY to $9.7M in FY 2025 from $9.2M.
• ·Turnaround costs remained relatively flat at $3.8M in FY 2025 versus $3.7M in FY 2024.
• ·Company does not report backlog, relying on long-term contract stability instead.
• ·Filing date: March 16, 2026

16-03-2026

Stoke Therapeutics reported revenue of $184M for 2025, up 404% YoY from $37M, driven by likely collaboration milestones, narrowing net loss to $7M from $89M and achieving positive cash flow from operations of $46M versus a $87M outflow prior year. However, operating expenses increased 49% YoY to $205M, with R&D up 55% to $138M and SG&A up 38% to $67M, while cash and equivalents declined to $84M from $128M amid heavy investing outflows of $187M. Total assets grew to $418M from $272M, bolstered by $97M in financing activities mainly from equity sales.

• ·Shares outstanding increased to 58.9M from 54.0M, driven by 3.2M shares from controlled equity offering ($88M net) and other issuances.
• ·Deferred revenue declined to $19M total (current $12M) from $19M (all current prior year).
• ·Stock-based compensation expense rose to $32M from $27M.
• ·Marketable securities totaled $307M (short $200M + long $106M) vs $119M prior year.

16-03-2026

Atara Biotherapeutics reported commercialization revenue of $120.8M for 2025, down 6% YoY from $128.9M, amid a sharp reduction in R&D expenses by 75% to $37.4M and G&A by 34% to $26.3M, driving a turnaround to operating income of $35.9M and net income of $32.7M versus prior-year losses of $83.4M and $85.4M. However, total cash and equivalents plummeted 80% to $8.5M from $42.5M, with net cash used in operating activities at $50.9M. Total assets shrank to $20.2M from $109.1M, though stockholders' deficit improved to $38.5M from $97.3M.

• ·Basic EPS $2.61 in 2025 vs ($11.41) in 2024.
• ·Shares issued and outstanding increased to 7,324 from 5,859.
• ·Deferred revenue dropped to $0.7M from $95.1M.
• ·Liability related to sale of future revenues: current $9.8M (2025) vs $0.4M (2024); long-term $32.7M vs $38.6M.